Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4 þ and CD8 þ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4 þ T cells that synthesized interleukin 2 (P ¼ 0.017), interferon-gamma (P ¼ 0.010), and tumor necrosis factor-alpha (P ¼ 0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4 þ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4 þ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.
Introduction
Chronic myelogenous leukemia (CML) is a malignancy of the hematopoietic stem cells resulting in the clonal expansion of myeloid cells and their progenitors. 1 At least 90% of cases have a cytogenetic abnormality known as the Philadelphia chromosome (Ph þ ), which results from a reciprocal translocation between chromosomes 9 (q34) and 22 (q11) . CML patients typically present in a chronic phase of the disease, which is a relatively indolent stage when precursors are differentiating into functional, mature hematopoietic cells. Recently, imatinib mesylate (IM), also known as Gleevec (Novartis, Basel, Switzerland) or STI-571, an inhibitor of BCR-ABL tyrosine kinase, has been shown to be a highly potent treatment for CML. 2 IM induces complete cytogenetic remission (CCR) in 74% of newly diagnosed CML patients and is also active in CML patients previously treated with interferon-alpha (IFN-a), with as many as 45% of these latter CML patients achieving CCR.
3,4 IM specificity is achieved through its high affinity for the ATPbinding pocket of specific target kinases, including Abelson kinase (c-ABL), the stem cell factor receptor c-kit, and the platelet-derived growth factor receptor. 5 This drug is well tolerated by patients with CML and other types of leukemia and does not produce the overt toxicity associated with conventional cancer therapy. Reuben et al 6 and Guarini et al 7 have shown that patients in chronic, accelerated, and blast-crisis phases of CML have a Th2 cytokine profile, whereas patients who are in CCR after treatment with IFN-a have a Th1 cytokine profile. Although IM is highly effective at inducing CCR in CML patients, a drawback of IM therapy is that it can also inhibit cytokine production by the T cells of healthy subjects 8 and suppress normal human T-cell proliferation in vitro in a dose-dependent manner. 9 Cytokines, especially interleukin (IL)-2, are necessary for T-cell proliferation, and together with interferon-gamma (IFN-g) and tumor necrosis factor-alpha (TNF-a), are necessary for an efficient T-cell-mediated immune response, whereas the Th2 cytokine IL-10 downregulates cell-mediated immunity. 10 As cytokines are essential mediators of host immunosurveillance mechanisms that are important for the eradication of CML, we investigate if IM inhibits cytokine synthesis by activated T cells of CML patients.
Materials and methods

Clinical staging and classification of patients with CML
The patient population consisted of patients with Ph þ CML in CCR receiving either IM or IFN-a as their primary treatment at The University of Texas MD Anderson Cancer Center who had consented to participate in this study approved by the institution's Human Experimentation Committee. At the time of the study, the patients provided a medical history, including information about prior treatments for CML, and underwent a physical examination, including determination of the performance status, disease stage, and response to treatment, according to previously defined criteria. 11 All patients had been in CCR for less than 2 years and were on maintenance therapy with either IM or IFN-a. Control subjects who self-reported to be in good health and not on any immunomodulatory medication were also recruited to participate in the study.
Intracellular cytokine synthesis by T cells in the presence of IM in autologous plasma
To assess the effect of IM in autologous plasma on the cytokine synthesis by T cells activated through protein kinase C (PKC), 1 ml of whole blood from each of 16 CML-IM patients, 19 CML-IFN patients, and 20 healthy controls was incubated with 25 ng of phorbol 12-myristate 13-acetate (PMA; Sigma Chemical Company, St Louis, MO, USA), 1 mg of ionomycin (Sigma), and 10 mg of brefeldin A (Sigma), a nontoxic but potent inhibitor of intracellular transport, 12 for 5 h at 371C.
To study the effect of IM in autologous plasma on the cytokine synthesis by T cells activated through the T-cell receptor (TCR), 1.5 ml of whole blood from each of 34 CML-IM patients, 34 CML-IFN patients, and 24 healthy controls was incubated with 3 mg/ml Staphylococcus enterotoxin B (SEB; Sigma) along with 3 mg/ml anti-CD28 and 3 mg/ml anti-CD49d (both from BD-Pharmingen, San Diego, CA, USA) at 371C for 5 h; brefeldin A was added to the cultures for the final 3 h of incubation. T cells activated with either PMA or SEB were stained for the presence of cytoplasmic cytokines, as previously described. 6 Intracellular cytokine synthesis by activated T cells in the absence of autologous plasma
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Ficoll-Hypaque density-gradient centrifugation and suspended in 'complete medium' consisting of RPMI-1640 (Whittaker Bioproduct, Walkersville, MD, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin (Whittaker Bioproduct), 100 mg/ml streptomycin (Whittaker Bioproduct), and 2 mM glutamine (GIBCO, Grand Island, NY, USA). PBMCs (6 Â 10 6 ) from each of 14 CML-IM patients and 15 healthy controls were suspended in 1.5 ml of complete medium that was supplemented with SEB, anti-CD28, and anti-CD49d (each at a final concentration of 3 mg/ml), and the cultures were incubated at 371C for 5 h. Brefeldin A was added to the cultures for the final 3 h of incubation. In addition, PBMC cultures were activated with a pan T-cell activator, anti-CD3, which was immobilized to the surface of a 24-well plate (Costar, Cambridge, MA, USA). Briefly, the bottom of each well of a 24-well plate was coated with 0.75 mg of anti-CD3 (Coulter Immunology, Hialeah, FL, USA), and the plate was incubated at 371C for 6 h. Thereafter, the plates were air-dried in a laminar flow hood. Anti-CD28 (1.5 mg) (BD Biosciences, San Jose, CA, USA) and 10 6 PBMCs in 1 ml of complete medium were added to each well of a 24-well plate coated with anti-CD3, and the plate was incubated at 371C for 16-18 h. In total, 10 mg of brefeldin A was added to each PBMC culture for the last 3 h of the incubation period. Next, 6 Â 10 6 activated PBMCs were harvested and reacted with monoclonal antibody reagents to detect the intracellular expression of cytokines, and the stained activated T cells were analyzed as described previously. 6, 13 Cytokine synthesis by anti-CD3-activated T cells in the presence of IM or autologous plasma 10 6 aliquots of PBMCs from CML-IM patients (N ¼ 14) were suspended in medium containing anti-CD28 and either 10% FBS plus 2.5 mM IM or 10% autologous plasma. Next, the PBMCs were dispensed into the individual wells coated with an antibody to CD3, and the plate was incubated at 371C for 16-18 h. In total, 10 mg of brefeldin A was added to each of the PBMC cultures for the last 3 h of the incubation period. Thereafter, the activated PBMCs were harvested for detection of intracellular cytokines, and the stained activated T cells were analyzed as previously described. 6, 13 Tyrosine phosphorylation of ZAP70 in PBMCs of CML patients
PBMCs from three CML-IM patients were isolated and washed in PBS before the isolated pellet was stored at À1401C. PBMCs collected from individual CML-IM patients before and after therapy with IM were lysed (on ice), and equal protein aliquots (30 mg) were analyzed for p(Y319)-ZAP70 and ZAP70 by immunoblotting and reprobed with antibody to ZAP70 (Cell Signaling Technology, Beverly, MA, USA) as a loading control. Jurkat cell lysate was used as a positive control. The clinical use of IM was the sole source of IM exposure in these PBMCs.
Statistical analysis
Statistical differences between the percentages of T cells synthesizing cytokines in the whole blood cultures of healthy controls, CML-IFN patients, and CML-IM patients in response to activation with PMA or SEB were examined by one-way analysis of variance, followed by Dunnett's T3 post test. Statistical differences between the percentages of T cells synthesizing cytokines in the PBMC cultures of healthy controls and CML-IM patients in response to TCR activation with either SEB or antibody to CD3 were determined by the nonpaired t-test. P-value less than 0.05 was considered statistically significant.
Results
Cytokine synthesis by T cells in whole blood
T-cell activation by PMA: The ability of T-cell subsets in autologous plasma to synthesize IL-2, IFN-g, TNF-a, or IL-10 in response to the activation of PKC with PMA was determined in 16 CML-IM patients, 19 CML-IFN patients, and 20 healthy controls. The percentages of CD4 þ and CD8 þ T cells that synthesized IL-2, IFN-g, and TNF-a after activation with PMA were similar for all groups ( Table 1 ). The percentage of CD4 þ T cells but not that of CD8 þ T cells that synthesized IL-10 after activation with PMA was higher for CML-IFN patients than CML-IM patients (P ¼ 0.032) and healthy controls (P ¼ 0.036).
T-cell activation by SEB:
The ability of CD4 þ and CD8 þ T cells in autologous plasma to synthesize IL-2, IFN-g, TNF-a, or IL-10 in response to the activation of TCR by SEB was determined in 68 CML patients (34 CML-IM and 34 CML-IFN) and 24 healthy controls. The cultures of whole blood from patients treated with IM had significantly lower percentages of CD4 þ T cells that synthesized IL-2 (P ¼ 0.017), IFN-g (P ¼ 0.010), and TNF-a (P ¼ 0.009) than those from healthy controls when TCR was activated in the presence of autologous plasma (Table 2) . CML-IFN patients and healthy controls had similar percentages of SEB-activated CD4 þ T cells that produced these cytokines. All groups had similar percentages of SEB-activated CD8 þ T cells that synthesized IL-2, IFN-g, TNF-a, and IL-10.
Cytokine synthesis by T cells in the absence of autologous plasma T-cell activation by SEB: Samples of IM from CML-IM patients that were activated with SEB resulted in fewer activated CD4 þ T cells that were capable of synthesizing cytokines. These findings indicate that the autologous plasma of CML-IM patients may impair cytokine synthesis by activated CD4 þ T cells. As the half-life of IM is 18 h 14 and CML-IM patients were on maintenance therapy at the time of this study, we investigated whether cytokine synthesis by activated T cells would be suppressed if the cells were activated in the absence of autologous plasma. In RPMI-1640 medium supplemented with 10% FBS, SEB-activated PBMCs of the CML-IM patients and control subjects had similar percentages of CD4 þ T and CD8 þ T cells that synthesized IL-2, IFN-g, TNF-a, and IL-10 (Table 3) .
Cytokine synthesis by T cells activated by immobilized anti-CD3: To further investigate the activation of T cells in the absence of autologous plasma, PBMCs suspended in RPMI-1640 medium supplemented with 10% FBS from 14 CML-IM patients and 15 healthy controls were activated with an immobilized antibody to CD3 and a soluble antibody to CD28 before the cytokine synthesis by T-cell subsets was measured. Under these culture conditions, the CML-IM patients and healthy controls had similar percentages of CD4 þ and CD8 þ T cells that synthesized IL-2, IFN-g, TNF-a, and IL-10 (Table 4) . These findings indicate that the activation of T cells in the presence of autologous plasma that contained IM may be responsible for the inhibition of cytokine synthesis by the T cells of CML patients on maintenance therapy with IM.
The effect of exogenous IM on the synthesis of cytokines by T cells activated with an immobilized antibody to CD3
To confirm our hypothesis that IM inhibits cytokine synthesis by activated T cells, the PBMCs of seven CML-IM patients, suspended in 10% FBS, were untreated or preincubated with a Cytokine synthesis suppressed by imatinib mesylate H Gao et al clinically relevant dose of 2.5 mM IM for 30 min before the cultures were activated with an immobilized antibody to CD3 and a soluble antibody to CD28. Cultures of PBMCs pretreated with exogenous IM followed by activation with an immobilized antibody to CD3 had contained significantly lower percentages of CD4 þ , but not CD8 þ , T cells that synthesized IL-2 (P ¼ 0.025), IFN-g (P ¼ 0.048), and TNF-a (P ¼ 0.018) than cultures of untreated PBMCs from the same patient (Table 5) .
To determine the effect of IM in the plasma of patients on the cytokine synthesis by activated T cells, PBMCs of a representative CML-IM patient were suspended in either 10% FBS or 10% autologous plasma and then activated with an immobilized antibody to CD3 and a soluble antibody to CD28. Cultures of PBMCs from CML-IM patients that were activated in the presence of 10% autologous plasma contained lower percentages of CD4 þ T cells that synthesized IL-2, IFN-g, and TNF-a than the PBMC cultures that were activated in the presence of 10% FBS (Figure 1a) . The suppression of cytokine synthesis was more pronounced in CD4 þ T cells than in CD8 þ T cells (Figure 1b) .
Cytokine synthesis by anti-CD3-activated CD4
þ T cells before and after IM therapy
To determine whether cytokine synthesis by CML patients is modified with the initiation of therapy with IM, cytokine synthesis by CD4 þ T cells was studied in two CML patients before treatment (at a dose of 400 mg twice a day), and then 5 days later. One of the patients received hydroxyurea as a cytoreductive therapy prior to IM therapy (Figure 2a ). The other patient had received IFN-a therapy, but it failed (Figure 2b) . Before treatment and at 5 days after IM therapy, PBMCs from both patients were suspended in RPMI-1640 medium containing 10% autologous plasma and activated with an immobilized antibody to CD3 and an antibody to CD28. In both cases, the percentages of CD4 þ T cells that synthesized IL-2, IFN-g, and TNF-a after treatment with IM were lower than those of CD4 þ T cells that synthesized these cytokines before therapy with IM. Cytokine synthesis by (a) CD4 þ and (b) CD8 þ T cells in PBMC cultures of a representative CML-IM patient. PBMCs were activated with an immobilized antibody to CD3 and a soluble antibody to CD28 in the presence of 10% FBS or 10% autologous plasma (plasma).
Effect of IM on the tyrosine phosphorylation of ZAP70
To determine whether the clinical use of IM has unintended effects on T-cell signaling, we analyzed samples of PBMCs obtained from CML patients before and after the initiation of IM therapy for ZAP70 tyrosine phosphorylation and expression. IM therapy suppressed the tyrosine phosphorylation of ZAP70 at clinical doses, but differences in the extent of inhibition and kinetics were noted (Figure 3a) . In addition, we examined ZAP70 phosphorylation and expression in a CML patient who developed resistance to IM and had to discontinue therapy. Both ZAP70 and its tyrosine phosphorylation were detected in this patient after withdrawal from IM therapy, suggesting that ZAP70 inhibition by IM is reversible in T cells from CML patients (Figure 3b) . These results also suggest that IM suppresses the ZAP70 signaling pathway in CML patients.
Discussion
In the current study, the CML-IFN patients and healthy subjects had similar percentages of T cells that produced the Th1 cytokines IL-2, IFN-g, and TNF-a after activation with PMA, an activator of PKC, 15 or SEB, an activator of the TCR. 16 By contrast, the percentage of PMA-activated CD4 þ T cells that synthesized the Th2 cytokine, IL-10, was higher in the CML-IFN patients than in the healthy controls and CML-IM patients (Table 1) , a finding that is consistent with the ability of IFN-a to induce IL-10 production by PMA-activated T cells. 17 Because PKC has no homology to the Src-family kinases, it is unlikely that IM would have any effect on PKC activity. Thus, it is reasonable that the CML-IM patients and healthy subjects had similar percentages of T cells that produced the Th1 cytokines IL-2, IFN-g, and TNF-a after activation with PMA.
Normal T-cell proliferation is suppressed by IM in a dosedependent manner. 9 In our preliminary experiments, T cells harvested from healthy donors were treated with IM and activated with immobilized antibody to CD3 and an antibody to CD28 or left untreated before analysis of ZAP70 and LCK phosphorylation. This showed that IM suppressed ZAP70 activation but had little effect on LCK phosphorylation (data not shown). Thus, the suppression of cytokine synthesis by SEBactivated CD4 þ T cells in the whole blood of CML-IM patients (Table 2 ) may be related to the exposure of T cells to IM in the plasma of the whole blood cultures of CML-IM patients at the time of study. Because the half-life of IM in plasma is approximately 18 h, at the recommended doses of 400 or 600 mg daily for 7 days, approximately 20% of the dose can be detected in the patients' plasma.
14 Although the plasma levels of IM were not determined in the present study, it is likely that CML-IM patients would have had detectable plasma levels of IM. Evidence implicating IM in the suppression of cytokine synthesis by the activated CD4 þ T cells of CML-IM patients includes the detection of suppression by SEB-activated CD4 þ T cells in whole blood cultures (Table 2 ) and CD4 þ T cells in 10% autologous plasma that were activated with an immobilized antibody to CD3 (Figure 1) but not in cultures of CD4 þ T cells suspended in 10% FBS and activated with an immobilized antibody to CD3 (Table 4) . Moreover, the addition of exogenous IM at a clinically relevant dose to PBMC cultures of CML-IM IM suppresses the tyrosine phosphorylation of ZAP70 of CML patients. (a) PBMCs obtained from two CML patients before and after initiation of IM therapy (patient #1, 600 mg by mouth, daily; patient #2, 400 mg by mouth, daily) were analyzed for activated ZAP70. IM therapy suppressed the tyrosine phosphorylation of ZAP70 at either clinical dose, but differences in the extent of inhibition and kinetics were noted. (b) In addition, blood samples were obtained from another CML patient during IM therapy (but samples from this patient before IM therapy were not available for study). The patient progressed (blast crisis), and a blood sample was obtained 1 week after imatinib therapy was withdrawn and compared with previous specimens for pY319-ZAP/ZAP70 by immunoblotting. Activated ZAP70 was recovered following withdrawal from imatinib therapy.
patients further implicates IM as a potential immunosuppressive agent (Table 5) . Taken together, these findings strongly support our belief that the presence of IM at the time of activation mediates the suppression of cytokine synthesis by activated CD4 þ T cells. In addition to the requirement that IM be present at the time of T-cell activation, the mechanism of suppression depends on the pathway employed for T-cell activation. In the current study, we activated T cells through the PKC pathway using PMA or through the TCR pathway using either SEB or an immobilized antibody to CD3. Cytokine synthesis was suppressed after the activation of CD4
þ , but not CD8 þ , T cells through the TCR pathway by either SEB (Table 2) or the immobilized antibody to CD3 (Table 5 ), but not through activation of the PKC pathway ( Table 1 ). The differential effects on the activation of CD4 þ and CD8 þ T cells through the TCR pathway and the resultant cytokine synthesis may be explained by the activation of the TCR and downstream signaling pathways of the CD4 and CD8 molecules. 18, 19 During TCR-mediated signaling, CD4 and CD8 surface molecules actively participate as coreceptors to enhance antigen responsiveness. 16 Although signaling through the CD4 and CD8 molecules depends initially on tyrosine kinase activation, CD4 þ T cells may rely more on TCR-associated tyrosine kinases than CD8 þ T cells do. 20 IM is known to suppress the phosphorylation of LCK and ERK1/2, both kinases associated with TCR-mediated signaling, 21 and may account for the suppression of cytokine synthesis by CD4 þ T cells of CML patients treated with IM. Our preliminary study of PBMCs from two CML patients obtained before and after the initiation of IM therapy indicated that IM therapy suppressed the tyrosine phosphorylation of ZAP70 (Figure 3a) . In addition, analysis of samples obtained from another CML patient during IM therapy and after withdrawal from IM therapy suggested that the IM-mediated suppression of tyrosine phosphorylation of ZAP70 is reversible. These results on primary T-cell cultures from CML patients receiving IM therapy corroborated the findings of a recent study showing that tyrosine phosphorylation of ZAP70 in IM-treated Jurkat cells activated through TCR was substantially reduced. 22 IM reduced the levels of phosphorylated kinases, and the downstream cytokine synthesis by CD4 þ T cells of a CML patient was noticeably reduced when activated through the TCR pathway in the presence of autologous plasma (Figure 1) . Moreover, in two CML-IM patients whose prior therapy had failed (Figure 2 ), the suppression of cytokine synthesis by IM occurred irrespective of prior therapy.
Our current findings that cytokine synthesis by the activated T cells was reduced further illustrate the potential suppressive effect of IM on T-cell immunity. We recently reported on a cluster of cases of Varicella-Zoster virus infection in CML patients treated with IM, a rare complication of CML patients who have not undergone stem cell transplantation. 23 Episodes of Varicella-Zoster viral infection result from the reactivation of a latent virus and are frequently seen in immune compromised patients, cancer patients receiving immunosuppressive therapy, and individuals with less than adequate CD4 þ T-helper function. 24, 25 The preferential synthesis of IL-2 by CD4 þ T cells is desirable for the development of leukemia-specific cytotoxic T lymphocytes in CML patients 26 because IL-2 is needed for the proliferation of these lymphocytes. 27 Although clinically significant immune suppression is yet to be reported in CML patients, the unintended inhibition of the cytokine synthesis of activated T cells by IM raises clinical concerns regarding the sustained use of this agent in CML.
